Conference day one (Wednesday 22nd February)
Registration opens
Developing effective evidence for rare diseases - our story
Bio-similar, but different: establishing (or defending) value through multi-criteria decision analytic (mcda) modelling
Deriving more value from RWE to ensure timely access of medicines by patients
• RWE as a means to develop strategic partnerships and alliances
• Challenges of realising the real value of RWE
The use of digital technologies in outcomes research
Speed networking
Morning refreshments
Using evidence to generate value based healthcare decisions
-What role of RWD in value based access decisions
-What future opportunities in terms of adaptive pricing/access
Short Presentation: Using RWE from a payer's perspective
Networking lunch
Chair's remarks
Developing an integrated, evidence based strategy for new indications
Rare disease registries: What have we learned from them?
Data that makes a difference: how electronic health care data can be used to support the clinical trial process
The future of RWE
Mini presentation - Aligning better regulators, HTA and patients
Afternoon refreshments
Early evidence development for new products - planning for reimbursement success
Panel Discussion: Bringing all stakeholders together in healthcare to improve pricing, value and access
Networking party
Organiser
